FDS - PDS Symposium IX: Speakers

Welcome

Julia Beaver, MD
Chief of Medical Oncology, Oncology Center of Excellence
US Food and Drug Administration
Bill Louv, PhD
President
Project Data Sphere

Keynote Address: Rare cancer registries – Impact on clinical practice, drug development and regulators

David Fajgenbaum, MD, MBA, MSc, FCPP
Assistant Professor of Medicine, Translational Medicine & Human Genetics
University of Pennsylvania Medical School

Panel 1: How do rare cancer registries impact clinical decision making?

Dave Reese, MD
Executive Vice President, Research and Development
Amgen, Inc.
David Miller, MD, PhD, FAAD
Medical Oncologist / Massachusetts General Hospital
Gregory Reaman, MD
Associate Director, Pediatric Oncology, Oncology Center of Excellence /US Food and Drug Administration
Ting Yu, MD, MS
Global Medical Director /EMD Serono, A business of Merck KGaA, Darmstadt, Germany

Panel 2: How do rare cancer registries advance drugs in development?

Zhen Su, MD, MBA
Senior Vice President, Head of US & Global Oncology Franchise
EMD Serono, A business of Merck KGaA, Darmstadt, Germany
Martha Donoghue, MD
Pediatric Solid Tumors Scientific Liaison
US Food and Drug Administration
Gregory Friberg, MD
Vice President Global Development, Therapeutic Area Head Heme/Onc & Bone
Amgen, Inc.
Michael Wong, MD, PhD, FRCPC
Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center

Fireside Chat: What is the potential of patient registries based on genomic alterations?

Sean Khozin, MD, MPH
Vice President Global Head of Data Strategy
Janssen Research & Development, LLC
Josh Bilenker, MD
Chief Executive Officer
Loxo Oncology, Inc. (a wholly owned subsidiary of Eli Lilly and Company)

Call to Action

Andy Crighton, MD
Chief Executive Officer
CEO Roundtable on Cancer and Project Data Sphere